Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review.
Two of the largest-ever biotech initial public offerings (IPOs) are scheduled to go ahead in the coming week, after a flurry of smaller stock market launches last week.
Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.
The 35-day US government shutdown has not just played havoc at government-run agencies – it has had a knock-on effect on the stock market because of cutbacks at the Securities and Exchange
RNA drug specialist Moderna smashed the record for an initial public offering (IPO) in the US on Friday, raising a whopping $604 million, although its shares retreated 19% after the debut.